| Resistance to molecularly targeted therapies in melanoma M Patel, A Eckburg, S Gantiwala, Z Hart, J Dein, K Lam, N Puri Cancers 13 (5), 1115, 2021 | 47 | 2021 |
| Treatment of metastatic melanoma with a combination of immunotherapies and molecularly targeted therapies T Rager, A Eckburg, M Patel, R Qiu, S Gantiwala, K Dovalovsky, K Fan, ... Cancers 14 (15), 3779, 2022 | 26 | 2022 |
| Mediating EGFR-TKI resistance by VEGF/VEGFR autocrine pathway in non-small cell lung cancer C Osude, L Lin, M Patel, A Eckburg, J Berei, A Kuckovic, N Dube, ... Cells 11 (10), 1694, 2022 | 18 | 2022 |
| Potential telomere-related pharmacological targets J Berei, A Eckburg, E Miliavski, AD Anderson, RJ Miller, J Dein, ... Current Topics in Medicinal Chemistry 20 (6), 458-484, 2020 | 16 | 2020 |
| PRMT-1 and p120-Catenin as EMT Mediators in Osimertinib Resistance in NSCLC KS Racherla, K Dovalovsky, M Patel, E Harper, J Barnard, ... Cancers 15 (13), 3461, 2023 | 3 | 2023 |
| Resistance to Molecularly Targeted Therapies in Melanoma. Cancers 2021, 13, 1115 M Patel, A Eckburg, S Gantiwala, Z Hart, J Dein, K Lam, N Puri s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2021 | 3 | 2021 |
| A metabolic axis of immune intractability DC Hinshaw, M Patel, LA Shevde Cancer immunology research, OF1-OF5, 2023 | | 2023 |
| Abstract 6347A: Promotion of low-dose computed tomography for early-stage lung cancer detection S Gautam, RE DeVera IV, M Patel, N Puri Cancer Research 82 (12_Supplement), 6347A-6347A, 2022 | | 2022 |
